Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

34° Sunny
- Bishop, CA (93514)
  Today
  
  Sunny. Near record high temperatures. High 72F. Winds light and variable..
  
  Tonight
  
  A clear sky. Low 32F. Winds light and variable.
  
  Updated: December 11, 2025 @ 7:24 am
- Full Forecast

Site search

Home
News
Sports
Obituaries
e-Edition
Special Sections
Classifieds
- Place an ad
Archives

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.29 -0.91 (-4.10%)

Streaming Delayed Price Updated: 11:23 AM EST, Dec 11, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

33 34 Next >

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

February 12, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years ↗

January 27, 2025

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.

Via Benzinga

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

January 27, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

January 13, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts ↗

December 19, 2024

Via Benzinga

Analyst Expectations For Sarepta Therapeutics's Future ↗

November 25, 2024

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

February 25, 2025

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.

Via StockStory

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

February 19, 2025

Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 14, 2025

Via Benzinga

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

February 14, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

2 Growth Stocks to Buy Hand Over Fist in February ↗

February 09, 2025

Via The Motley Fool

What 14 Analyst Ratings Have To Say About Sarepta Therapeutics ↗

January 15, 2025

Via Benzinga

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development ↗

January 08, 2025

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.

Via Benzinga

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 06, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 31, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

December 18, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst ↗

December 13, 2024

Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.

Via Benzinga

Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗

December 01, 2024

8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.

Via Benzinga

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗

December 01, 2024

Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.

Via Benzinga

Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30 ↗

November 30, 2024

Via Talk Markets

Topics Stocks / Equities

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 29, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? ↗

November 26, 2024

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT)....

Via Benzinga

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

November 26, 2024

Via Benzinga

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta ↗

November 26, 2024

The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.

Via Investor's Business Daily

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

November 26, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

November 25, 2024

Via Benzinga

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 07, 2024

Via Benzinga

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 07, 2024

Via Benzinga

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript ↗

November 07, 2024

SRPT earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Local Events
Obituaries
Multimedia
Online Features
Announcements

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

Contact Information

InyoRegister.com
407 W. Line St. #8
Bishop, CA 93514
Phone: 760-873-3535

Advertising

Retail Sales: egalanski@inyoregister.com
Classified Sales: classy@inyoregister.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Bishop, CA (93514)

Today

Tonight

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock

Sections

Services

Contact Information